Research Topics
| Roy M FleischmannSummaryAffiliation: Radiant Research Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanerceptRoy Fleischmann
Radiant Research Dallas, Dallas, Texas 75235, USA
Drug Saf 25:173-97. 2002..Preliminary data show that it may be well tolerated and effective in other rheumatic diseases in which there is over production of TNFalpha...- Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritisRoy Fleischmann
Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235 5360, USA
Expert Opin Biol Ther 4:1333-44. 2004..Anakinra should not be given in combination with anti-TNF agents... - Is there a need for new therapies for rheumatoid arthritis?Roy M Fleischmann
University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas, USA
J Rheumatol Suppl 73:3-7; discussion 29-30. 2005..This approach will be examined in this and the following articles... - Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trialR M Fleischmann
Radiant Research Dallas, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 75235, USA
Curr Med Res Opin 21:1181-90. 2005..We evaluated the ability of patients receiving infliximab plus MTX to achieve and maintain a clinical response while the dose of MTX was tapered... - Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxibRoy Fleischmann
University of Texas Southwestern Medical Center, Radiant Research Dallas, 5939 Harry Hines Boulevard, Dallas, 75235, USA
Clin Rheumatol 25:42-53. 2006..Lumiracoxib demonstrated a tolerability profile similar to placebo and celecoxib... - Long term safety of etanercept in elderly subjects with rheumatic diseasesR Fleischmann
University of Texas Southwestern Medical Center at Dallas, 5939 Harry Hines Boulevard, Dallas, Texas 75235, USA
Ann Rheum Dis 65:379-84. 2006.... - Tacrolimus in rheumatoid arthritisRoy Fleischmann
University of Texas Southwestern Medical Centre at Dallas, USA
Expert Opin Pharmacother 7:91-8. 2006..This article reviews the pharmacodynamics, pharmacokinetics, clinical efficacy, safety and role of tacrolimus in the treatment of rheumatoid arthritis... - Safety of extended treatment with anakinra in patients with rheumatoid arthritisR M Fleischmann
University of Texas Southwestern Medical Center at Dallas, Radiant Research, 5939 Harry Hines Boulevard, Dallas, TX 75235, USA
Ann Rheum Dis 65:1006-12. 2006..To determine the safety profile of anakinra after extended exposure in a diverse clinical trial population of patients with rheumatoid arthritis... - Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?Roy M Fleischmann
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
Rheum Dis Clin North Am 32:21-8. 2006 - Anakinra in the treatment of rheumatic diseaseRoy Fleischmann
University of Texas Southwestern Medical Center at Dallas Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400 Dallas, TX 75235, USA
Expert Rev Clin Immunol 2:331-40. 2006.... - Does safety make a difference in selecting the right TNF antagonist?Roy Fleischmann
University of Texas Southwestern Medical Center, Dallas, TX, USA
Arthritis Res Ther 6:S12-8. 2004..Overall, the anti-TNF agents are well tolerated and have demonstrated a favorable benefit-to-risk profile in patients with RA... - Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritisRoy Fleischmann
University of Texas Southwestern Medical Center, Dallas, TX, USA
Mol Interv 3:310-8. 2003 - Addressing the safety of anakinra in patients with rheumatoid arthritisR M Fleischmann
St Paul University Hospital, Department of Rheumatology, Dallas, TX 75235, USA
Rheumatology (Oxford) 42:ii29-35. 2003..This confirmed that anakinra is a well-tolerated treatment in an RA population representative of that seen by the practising rheumatologist... - Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trialRoy M Fleischmann
St Paul University Hospital, Dallas, Texas 75235, USA
Arthritis Rheum 48:927-34. 2003..To evaluate the safety of anakinra (a recombinant human interleukin-1 receptor antagonist) in a large population of patients with rheumatoid arthritis (RA), typical of those seen in clinical practice... - MeloxicamRoy Fleischmann
University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA
Expert Opin Pharmacother 3:1501-12. 2002..Adverse events, including peripheral oedema and hypertension, occurred at a similar rate as with traditional NSAIDs... - Examining the efficacy of biologic therapy: are there real differences?Roy M Fleischmann
Department of Medicine, St Paul University Hospital, University of Texas Southwestern Medical Center, Dallas 75235, USA
J Rheumatol Suppl 65:27-32. 2002..All 3 biologics - anakinra, etanercept, and inflixmab - are effective... - Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritisRoy Fleischmann
University of Texas Southwestern Medical Center at Dallas, St Paul University Hospital, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235, USA
Expert Opin Drug Saf 2:347-65. 2003.... - Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agentsR M Fleishmann
University of Texas, Southwestern Medical Center at Dallas Dallas, Texas, USA
Clin Exp Rheumatol 20:S35-41. 2002..Post approval, several safety concerns, including patients at risk for serious infection and the emergence of latent tuberculosis and other opportunistic infections have emerged with the use of anti TNF therapy... - Considerations with the use of biological therapy in the treatment of rheumatoid arthritisRoy M Fleischmann
University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235-5360, USA
Expert Opin Drug Saf 3:391-403. 2004..It is important to be fully aware of the safety profile and differences between BRMs in order to use them appropriately... - Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial resultsRoy M Fleischmann
University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
J Rheumatol 30:691-6. 2003..CONCLUSION: Etanercept is a new treatment option for older patients with RA and has substantial benefit and comparable safety regardless of patient age... - Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst
Division of Rheumatology, Department of Medicine, University of California Los Angeles, 32 59 Rehabilitation Center, 1000 Veteran Avenue, Box 951670, Los Angeles, CA 90095 1670, USA
J Rheumatol 30:2563-71. 2003..Standard antirheumatic therapy included traditional disease modifying antirheumatic drugs (DMARD), low dose corticosteroids, nonsteroidal antiinflammatory drugs (NSAID), and/or analgesics... - Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidenceStanley B Cohen
The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
J Rheumatol Suppl 81:4-30; quiz 31-4. 2008..In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA... - Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese
Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
Arthritis Rheum 46:1443-50. 2002..To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy... - Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritisRoy Fleischmann
The University of Texas Southwestern Medical Center at Dallas, MCRC, Dallas, Texas, USA
BMC Musculoskelet Disord 9:32. 2008..d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year... - The efficacy and safety of golimumab in the treatment of arthritisRoy Fleischmann
University of Texas Southwestern Medical School, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, Texas 75231, USA
Expert Opin Biol Ther 10:1131-43. 2010..Biologic therapies have dramatically changed the long-term prognosis of patients with rheumatoid and psoriatic arthritis and ankylosing spondylitis... - Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximabRoy M Fleischmann
University of Texas Southwestern Medical Center, and Metroplex Clinical Research Center, Dallas, TX 75235 5360, USA
Semin Arthritis Rheum 38:265-80. 2009..To review the safety of biologic agents used to treat rheumatoid arthritis (RA) and other autoimmune diseases, with a focus on rituximab... - Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritisRoy Fleischmann
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
Drugs Aging 24:239-54. 2007..Only by understanding the risks and benefits of therapy in the older age group can a true risk : benefit profile for etanercept, and ultimately other anti-TNFalpha therapies, be determined by the practising physician and the patient... - Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritisJohn Tesser
University of Arizona Health Sciences Center, Arizona Rheumatology Center, Phoenix, Arizona 85015 2160, USA
J Rheumatol 31:649-54. 2004..To examine the safety of anakinra when added to a background of standard rheumatoid arthritis (RA) medications in patients with RA with active disease... - A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisDaniel E Furst
Department of Rheumatology, University of California at Los Angeles, California 90095, USA
J Rheumatol 32:2303-10. 2005..In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA)... - The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritisRoy Fleischmann
Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, Texas 75231, USA
Expert Opin Biol Ther 10:773-86. 2010..Another medication, such as certolizumab pegol, is a welcome addition to our treatment armamentarium of rheumatoid arthritis... - Primer: establishing a clinical trial unit - regulations and infrastructureRoy Fleischmann
University of Texas Southwestern Medical Center at Dallas, and Metroplex Clinical Research Center, Dallas, TX 75235, USA
Nat Clin Pract Rheumatol 3:234-9. 2007..The purpose of this article is to review these requirements in depth, as well as to discuss the infrastructure required to establish a successful clinical trial unit... - Primer: establishing a clinical trial unit--obtaining studies and patientsRoy Fleischmann
University of Texas Southwestern Medical Center, Dallas, TX, USA
Nat Clin Pract Rheumatol 3:459-63. 2007..If done properly, however, clinical investigation can be rewarding--both intellectually and financially... - Kinase inhibitors: a new approach to rheumatoid arthritis treatmentStanley Cohen
Metroplex Clinical Research Center, Dallas, Texas, USA
Curr Opin Rheumatol 22:330-5. 2010..This article will review the recent publications on these efforts... - Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou
Clinical Pharmacology and Experimental Medicine, Centocor Research and Development, 200 Great Valley Parkway, Malvern, PA 19355, USA
J Clin Pharmacol 47:383-96. 2007..0%. Body weight was found to be an important covariate on V(c). Golimumab was generally well tolerated. The pharmacokinetics of golimumab appeared to be linear over the dose range evaluated in this study... - Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disabilityScott W Baumgartner
Physician s Clinic of Spokane, Spokane, Washington 99204, USA
J Rheumatol 31:1532-7. 2004..To compare etanercept-induced improvement in disability of patients with recent onset of rheumatoid arthritis (RA) to that of patients with established RA... - Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritisMark C Genovese
Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
J Rheumatol 32:1232-42. 2005..To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept... - Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observationsJoel M Kremer
The Center for Rheumatology, Albany, New York 12206, USA
Arthritis Rheum 48:1493-9. 2003.... - Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritisJoan M Bathon
Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA
J Rheumatol 33:234-43. 2006..To evaluate safety and efficacy of etanercept treatment in elderly (age > or = 65 yrs) and younger adult subjects (age < 65 yrs) with rheumatoid arthritis (RA)...